Top Management Presentation Financial Results of FY2017 Q1

DAIICHI SANKYO CO., LTD Kazunori Hirokawa Executive Vice President and CFO

July 31, 2017

Forward-Looking Statements

2

Management strategies and plans, financial forecasts, future projections and policies, and R&D information that Daiichi Sankyo discloses in this material are all classified as Daiichi Sankyo’s future prospects. These forward looking statements were determined by Daiichi Sankyo based on information obtained as of today with certain assumptions, premises and future forecasts, and thus, there are various inherent risks as well as uncertainties involved. As such, please note that actual results of Daiichi Sankyo may diverge materially from Daiichi Sankyo’s outlook or the content of this material. Furthermore, there is no assurance that any forward-looking statements in this material will be realized. Regardless of the actual results or facts, Daiichi Sankyo is not obliged and does not have in its policy the duty to update the content of this material from the date of this material onward.

Compounds under discussion are investigational agents and are not approved by the FDA or any other regulatory agency worldwide as a treatment for indications under investigation. Efficacy and safety have not been established in areas under investigation. There are no guarantee that these compounds will become commercially available in indications under investigation.

Daiichi Sankyo takes reasonable care to ensure the accuracy of the content of this material, but shall not be obliged to guarantee the absolute accuracy, appropriateness, completeness and feasibility, etc. of the information described in this material. Furthermore, any information regarding companies, organizations or any other matters outside the Daiichi Sankyo Group that is described within this material has been compiled or cited using publicly available information or other information, and Daiichi Sankyo has not performed in-house inspection of the accuracy, appropriateness, completeness and feasibility, etc. of such information, and does not guarantee the accuracy thereof.

The information described in this material may be changed hereafter without notice. Accordingly, this material or the information described herein should be used at your own judgment, together with any other information you may otherwise obtain.

This material does not constitute a solicitation of application to acquire or an offer to sell any security in the United States, Japan or elsewhere.

This material disclosed here is for reference purposes only. Final investment decisions should be made at your own discretion.

Daiichi Sankyo assumes no responsibility for any damages resulting from the use of this material or its content, including without limitation damages related to the use of erroneous information

3

Agenda

FY2017 Q1 Financial Results

Major Management Topics Edoxaban Japan Business Injectafer Business Growth in China

R&D Update

4

FY2017 Q1 Financial Results

5

FY2016

Q1 Results FY2017

Q1 Results YoY

Revenue 241.0 239.1 -1.9

Cost of Sales 77.6 80.1 +2.5

SG&A Expenses 69.5 70.8 +1.3

R&D Expenses 46.6 48.0 +1.4

Operating Profit 47.3 40.3 -7.0

Profit before Tax 45.2 42.2 -3.0

Profit attributable to owners of the Company 30.6 29.2 -1.4

Currency Rate

USD/JPY 108.25 111.10 +2.85 EUR/JPY 122.17 122.19 +0.02

-0.8%

-14.8%

-4.7%

Overview of FY2017 Q1 Results

(Bn JPY)

6 * Forex impact USD: +1.4, ASCA: +0.4

Japan Positive : Lixiana +3.9 Nexium +1.5 Pralia +1.4 Daiichi Sankyo Espha +2.0 Negative : Olmetec -1.4 Daiichi Sankyo Healthcare (OTC) +2.0

Revenue

Positive Factors Negative Factors

Decreased by 1.9 Bn JPY (Decreased by 3.7 Bn JPY excl. forex impact) (Bn JPY)

Global (excl. Forex Impact) Daiichi Sankyo, Inc. : Olmesartan -16.6 Luitpold : GE injectables +3.0

Injectafer +1.9 Daiichi Sankyo Europe : Olmesartan -5.0 Lixiana +3.5 239.1

1.8*

0.8

1.9

4.9

16.4

8.9

241.0

FY2017 Results

Forex Impact

ASCA (Asia, South andCentral America )

Daiichi Sankyo Europe

Luitpold (US)

Daiichi Sankyo, Inc. (US)

Japan (incl. Vaccines, OTC)

FY2016 Results

7

Operating Profit

Positive Factors Negative Factors

Revenue -1.9 incl. forex impact +1.8

Forex impact +1.7 Cost of Sales +0.6 SG&A Expenses +0.6 R&D Expenses +0.5

Cost of Sales +1.8 Product mix due to impact of olmesartan LOE

Decreased by 7.0 Bn JPY (Decreased by 7.1 Bn JPY excl. forex impact and special items)

(Bn JPY)

40.3

42.8

45.4

47.3

0.0

1.7

0.9

0.7

1.8

1.9

FY2017 Results

Special Items

Forex Impact

R&D Expenses

SG&A Expenses

Cost of Sales

Revenue

FY2016 Results

8

Profit Attributable to Owners of the Company

Positive Factors Negative Factors

Financial Income / Expenses -3.9 Improvement of forex gains/ losses

Decreased by 1.4 Bn JPY (Bn JPY)

29.2

30.6

1.7

4.0

7.0

FY2017 Results

Income Taxes etc.

Financial Income/ Expenses etc.

Operating Profit

FY2016 Results

9

FY2016

Q1 Results FY2017

Q1 Results YoY vs. Forecast (%)

Japan 123.4 130.0 +6.6 24.3% Daiichi Sankyo Healthcare 14.8 16.8 +2.0 24.4% Daiichi Sankyo Inc. 40.7 25.0 -15.7 40.3% Olmesartan 23.2 6.8 -16.4 48.4% Welchol 10.0 10.1 +0.2 37.5% Effient 6.0 6.1 +0.1 - Savaysa 0.3 0.5 +0.2 24.1% Movantik 0.9 1.3 +0.4 - Luitpold 22.0 27.6 +5.6 26.8% Venofer 7.4 7.4 +0.0 26.4% Injectafer 5.9 8.1 +2.1 24.4% GE injectables 7.4 10.7 +3.3 - Daiichi Sankyo Europe 20.4 18.5 -1.9 28.1% Olmesartan 14.0 9.0 -5.0 34.5% Efient 2.3 1.9 -0.4 27.2% Lixiana 1.4 4.9 +3.5 22.3% ASCA (Asia, South and Central America) 17.7 19.0 +1.2 22.6%

Revenue: Major Business Units (Incl. Forex impact)

Currency Rate

USD/JPY 108.25 111.10 +2.85 EUR/JPY 122.17 122.19 +0.02

(Bn JPY)

10

FY2016

Q1 Results FY2017

Q1 Results YoY vs. Forecast (%)

Nexium ulcer treatment 21.0 22.6 +1.5 24.6% Memary Alzheimer’s disease

treatment 12.1 12.5 +0.4 23.2% Olmetec antihypertensive agent 18.3 16.8 -1.4 35.8% Lixiana anticoagulant 5.5 9.4 +3.9 24.0% Loxonin anti-inflammatory analgesic 10.3 9.6 -0.7 29.0% Tenelia type 2 diabetes mellitus treatment 6.7 7.6 +0.9 25.3% Pralia treatment for osteoporosis 4.1 5.5 +1.4 23.9% Rezaltas antihypertensive agent 4.7 4.5 -0.2 28.1% Ranmark treatment for bone complications caused

by bone metastases from tumors 3.4 3.8 +0.4 25.1% Efient antiplatelet agent 2.5 3.3 +0.8 25.4% Inavir anti-influenza treatment 0.6 0.7 +0.2 5.5% Cravit synthetic antibacterial agent 3.8 3.3 -0.4 25.4% Urief treatment for dysuria 3.0 2.9 -0.1 26.3% Omnipaque contrast medium 3.7 3.6 -0.0 33.1% Mevalotin antihyperlipidemic agent 2.9 2.4 -0.5 24.5%

Revenue: Major Products in Japan (Bn JPY)

11

Major Management Topics

12

Edoxaban Update

13

（%）

0

10

20

30

40

50

LixianaProduct AProduct BProduct C

20.5%

As of FY2017 Q1, Lixiana increased its sales share to 20.5%.

Copyright © 2017 QuintilesIMS Calculated based on JPM 2014 Q1-2017Q1 Reprinted with permission

Growth in Japan

14 Source ：Medi-trend

0

5

10

15

20

25

30

35(％) 34.2%

Lixiana has reached top Rxs share since Mar. 2017 in prescription number of new patients for AF+VTE. The share expanded to 34.2% in May 2017.

Growth in Japan

0.0%

1.0%

2.0%

3.0%

4.0%

5.0%

6.0%

7.0%

8.0%

Aug-

15Se

p-15

Oct

-15

Nov

-15

Dec-

15Ja

n-16

Feb-

16M

ar-1

6Ap

r-16

May

-16

Jun-

16Ju

l-16

Aug-

16Se

p-16

Oct

-16

Nov

-16

Dec-

16Ja

n-17

Feb-

17M

ar-1

7Ap

r-17

7.5%

15

Germany 16.2%

0.0%

2.0%

4.0%

6.0%

8.0%

10.0%

12.0%

14.0%

16.0%

18.0%

Jan-

16Fe

b-16

Mar

-16

Apr-

16M

ay-1

6Ju

n-16

Jul-1

6Au

g-16

Sep-

16O

ct-1

6N

ov-1

6De

c-16

Jan-

17Fe

b-17

Mar

-17

Apr-

17

South Korea

Steady uptake of sales share after launch

Copyright © 2017 QuintilesIMS Calculated based on MIDAS Sales Data Reprinted with permission

Growth in Germany and South Korea

Based on data from ENSURE-AF Following the positive opinion of European CHMP*1 for LIXIANA

(edoxaban) in patients with NVAF undergoing cardioversion, SmPC of LIXIANA was updated in “Posology and method of administration“. Approx. 24 % of newly diagnosed AF patients estimated to

undergo cardioversion*2.

The label update provides guidance on LIXIANA use in NVAF patients undergoing cardioversion. Physicians now rely on the guidance and use LIXIANA for such patients with more confident than ever.

16

Clinical Setting (Comparator)

Primary Outcome Presentaion

Cardioversion (enoxaparin/warfarin)

• Stroke, SEE, MI, CV mortality

• Major and CRNM bleeding ESC 2016

*1: Committee for Medicinal Products for Human Use *2: Nabauer M., et al. Europace (2009) 11, 423–434

LCM update

17

Japan Business Update

18

Approval for PRALIA for additional indication (July 2017) Indications: Inhibition of the progression of bone erosion*1

associated with rheumatoid arthritis Denosumab's approval for rheumatoid arthritis

is first in the world First product to have both indications

for osteoporosis and rheumatoid arthritis About 45% of RA patients complicated with osteoporosis*2

Approval for CANALIA combination tablets (July 2017)

Combination product of Tenelia and Canaglu tablets, two agents for type 2 diabetes mellitus treatments, created by Mitsubishi Tanabe Pharma Corporation

Marketing by Daiichi Sankyo, and co-promoting with Mitsubishi Tanabe DPP-4 inhibitor/SGLT2 inhibitor combination drug, first approval in Japan

*1: Bone erosion is a radiological term and reflects the fact that imaging is used for detection. Erosions are visible on plain radiographs as breaks and holes in the bone surface. *2: 2010 Rheumatism White Paper (The Japan Rheumatism Friendship Association)

Expansion of Product Portfolio in Japan

19

Strengthen authorized generic (AG) business through Daiichi Sankyo Espha Launched telmisartan (original brand name: Micardis)

and its combination products (June 2017) Launch olmesartan and rosuvastatin (original brand name: Crestor)

in September ahead of competitors' generics

Launch of Narurapid and Narusus for cancer pain treatment (June 2017) Indications: Analgesic for moderate to severe cancer pain Developed as unapproved drugs and indications with high medical needs

in Japan

Expansion of Product Portfolio in Japan

20

Injectafer Update

0

100

200

300

400

500

600

700

800

900

MAT May2015

MAT May2016

MAT May2017

10

15

20

25

30

Apr

May Jun

Jul

Aug

Sep

Oct

Nov Dec Jan

Feb

Mar

Apr

May Jun

($M)

14.1% 25.8%

32.2%

56.6% 48.2% 42.5%

($M)

26.2

US IV Iron Market (includes dialysis)

Injectafer*

Venofer

*Injectafer is not indicated for patients who are dialysis dependent

Source: IMS National Sales Perspectives May 2017 (includes all US IV Iron sales in all channels including dialysis chains)

Copyright © 2017 QuintilesIMS. Reprinted with permission

Injectafer Monthly Revenue

593.4

690.3

786.6

Expanding monthly revenue under the integrated team (Daiichi Sankyo, Inc. and Luitpold) launched in Jan 2017

2016 2017 21

Growth of Injectafer

22

Injectafer Life-Cycle Management

Iron deficiency is a comorbid

condition in 50% of HF patients

HF prevalence

has increased 5.8 million (2014)

Americans ≥20 years of age.

Heart Failure : HEART-FID (Phase 3 Study)

Randomized, double-blind, placebo-controlled study for patients in heart failure (HF) with reduced ejection fraction (HFrEF) with iron deficiency (ID) FDA Agreement of Special Protocol Assessment to conduct a single pivotal study in HF Enrolling more than 3,000 adults across North America, Australia and New Zealand Primary composite outcome measure includes: 12-month rate of death 12-month number of hospitalizations for worsening HF 6-month change in 6-minute walk test

Started March 2017; expected completion in 2022

Restless Leg Syndrome (RLS) A phase 2, randomized, placebo-controlled study, investigators will assess the efficacy and safety of Injectafer for the treatment of RLS in patients with IDA.

23

Business Growth in China

2015 2016 2017

Sales promotion activities of each product by partners through alliance initially started from outside of major cities

Partnering has expanded into major cities since April 2016

Products Alliance Start

Alliance Expansion

Olmetec 2015.12

2016.4

Olmetec HCTZ 2015.12 Cravit 2015.1

Asmeton 2013.9 Mevalotin 2012.7

Loxonin tablets 2014.2 Loxonin tape 2016.1

1,815

2,096

+15%

Over 20% growth in FY2017

Mn CNY

<Revenue>

FY2017 Forecast

<Major Alliances>

FY2015 Results

FY2016 Results 24

Establish Efficient Structures and Expand Revenue

To maximize revenue and profit of products

25

Daiichi Sankyo Pharmaceutical (Beijing) Co., Ltd. [Beijing Factory]

A new facility for solid-form drugs will be activated in FY2018. <Olmesartan family, etc.>

Daiichi Sankyo Pharmaceutical (Shanghai) Co., Ltd. [Shanghai Factory]

A new manufacturing line for injectable drugs has been activated since Jan. 2017. <Cravit IV>

Enhance Production Capacity for Business Expansion

26

R&D Update

27

Phase 3 studies Result (primary endpoint*)

US/EU Fibromyalgia (FM) –E309 Not-achieved Fibromyalgia (FM) –E310 Not-achieved Fibromyalgia (FM) –E311 Not-achieved

Japan/ Asia

Post-herpetic neuralgia (PHN) Achieved Diabetic peripheral neuropathic pain (DPNP) TLR by September 2017

Future schedule US/EU Comprehensive analysis including all studies will be conducted to

determine NDA strategy after obtaining TLR of DPNP Japan/Asia NDA strategy and timing will be determined after obtaining TLR of DPNP

- Data disclosure at scientific conferences planned in FY2018

*comparison to placebo

Mirogablin: Phase 3 Result and Future Schedule

28

Presentation at ASCO 2017

DS-8201（HER2-ADC） Progress of ongoing phase 1 study (oral) Immune response of DS-8201 (poster)

U3-1402（HER3-ADC） Study design of ongoing phase 1/2 study (poster)

DS-8201: ASCO 2017 (Oral)

29

Tumor size reductions were seen in most patients (reduction is bigger when the bar goes down lower than 0%)

DS-8201: ASCO 2017 (Oral)

ORR was 45.7% in BC patients with prior treatment of T-DM1 (Kadcyla) ORR was 44.4 % in GC patients with prior treatment of CPT-11 (irinotecan)

30

DS-8201: ASCO 2017 (Oral)

31

Tumor reductions confirmed from beginning of treatment and reductions are continuing

DS-8201: ASCO 2017 (Oral)

32

Median PFS has reached 45.4 weeks Approximately 80% of patients continue treatment with DS-8201

DS-8201: ASCO 2017 (Oral)

33

Median PFS has reached 27.3 weeks Approximately 50% of patients continue treatment with DS-8201

DS-8201: ASCO 2017 (Oral)

34

No dose-limiting toxicity (DLT) was seen Low incidence of grade 4 adverse events

DS-8201: ASCO 2017(Poster)

35

Presented immune response of DS-8201

*1 Dendritic cells are a type of antigen-presenting cell that form an important role in the adaptive immune system *2 MHC-Class I deliver short peptides to the cell surface allowing these peptides to be recognized by T cells *3 PD-L1 is a protein on tumor cell. When PD-L1 attach to receptors on T cells called PD-1, it inactivate T cells.

Purpose To analyze MOA of combination benefit of DS-8201 and anti PD-1 antibody by using syngeneic mouse model

Result When tumor cell was re-challenged to cured mice that were treated with DS-8201, it was rejected. Thus, activation of antitumor immunity was confirmed. • Up-regulated dendritic cell*1 marker • Up-regulated MHC-Class I*2 on tumor cells • Up-regulated PD-L1*3 on tumor cells

Conclusion This finding suggests that DS-8201 has ability to activate antitumor immunity and may have additional benefit of combining with immune checkpoint inhibitor

Details will be disclosed in scientific journal.

Presented Phase 1/2 study design Target population: HER3 positive refractory/metastatic breast

cancer Study status: Cohort 1 (1.6mg/kg): completed without dose-liming toxicity (DLT) Cohort 2 (3.2mg/kg): dosing continues

36

Escalation

1.6mpk

3.2mpk

4.8mpk

6.4mpk

Finding

During DLT evaluation During RP2D determination

About 80 pts

Expansion (Single Arm)

*RP2D : Recommended Ph2 dose

DLT

Phase 1 Phase 2

During RP2D evaluation

RP2D*

About 40 pts

Cohort 2

Cohort 1

Recommended phase 2 dose will be determined through dose escalation and dose finding parts.

U3-1402: ASCO 2017 (Poster)

December 2017

HER2 positive and HER2 low breast cancer

September 2017

HER2 positive solid tumor (eg colon cancer ) excluding breast and gastric cancer

DS-8201: Future Schedule Future data disclosure (Planned)

HER2+ Breast (T-DM1 failure)

HER2+ Gastric (Herceptin failure)

FY2017 FY2018 FY2019 Clinical trial schedule

Pivotal Phase 2 (JP/US/EU) Planed to start FY2017 Q2

Pivotal Phase 2 (JP/Korea) Planed to start FY2017 H2

HER2+ Breast

(T-DM1 resistance or refractory)

HER2+ Gastric (Herceptin resistance

or refractory)

Ph1

FY2020

Ph1

37

Clinical trial schedule

U3-1402: Future Schedule

Future milestone HER3 positive refractory/metastatic breast cancer TLR: FY2018 Q4 Start of EGFRm NSCLC study: FY2017 Q3

Phase 1 study (start from FY2017 Q3) EGFRm NSCLC

FY2017 FY2018

Phase 1/2 study (Dec 2016~) HER3 positive refractory/metastatic breast cancer

FY2019

☆TLR

38

DS R&D Day 2017

Date: December 13, 2017 in the afternoon

Location: Daiichi Sankyo Headquarter Office

Presenters: Dr. Glenn Gormley (Sr. Executive Officer, Global R&D Head) Dr. Antoine Yver

(Global Head of Oncology R&D, Head of Daiichi Sankyo Cancer Enterprise)

39

FY2017 Major R&D Milestone Events

*TLR: Top Line Results 40 Red: Update

Project Indication/Study Q1 Q2 Q3 Q4 FY18-Q1

Denosumab Rheumatoid arthritis (JP) Approved

CL-108 Pain/Opioid-induced nausea and vomiting (US) Re-submission

Mirogabalin

Fibromyalgia Phase 3 study (US/EU) TLR

PHN Phase 3 studies（JP/Asia） TLR

DPNP Phase 3 studies（JP/Asia） TLR

Pexidartinib Tenosynovial giant cell tumor Phase 3 study (US/EU) TLR Submission

Quizartinib QuANTUM-R AML 2nd line treatment Phase 3 study (US/EU/Asia)

Interim Analysis TLR

Esaxerenone (CS-3150)

Hypertension Phase 3 study（JP） TLR Submission

Diabetic nephropathy Phase 3 study (JP) Study initiation

DS-8201

HER2-positive Breast Cancer（T-DM1 resistance or refractory） Phase 2 study (pivotal) (JP/US/EU)

Study initiation

HER2-positive Gastric Cancer （Herceptin resistance or refractory) Phase 2 study (pivotal) (JP/Korea)

Study initiation

U3-1402 EGFRm NSCLC Phase 1 study Study initiation

DS-5141 Duchenne Muscular Dystrophy Phase 1/2 study (JP)

SAKIGAKE TLR

Phase 1 Phase 2 Phase 3 Application Therapeutic area

Cardiovascular- Metabolics

Oncology

Others

Edoxaban (JP) (DU-176b / AF / FXa inhibitor)

Prasugrel (JP) (CS-747 / Ischemic stroke / Anti- platelet agent)

Esaxerenone (JP) (CS-3150 / Hypertension / MR antagonist)

Edoxaban (ASCA etc.) (DU-176b / AF / FXa inhibitor)

Edoxaban (ASCA etc.) (DU-176b / VTE / FXa inhibitor)

Denosumab (JP) (AMG 162 / Breast cancer adjuvant / Anti-RANKL antibody)

Nimotuzumab (JP) (DE-766 / Gastric cancer / Anti-EGFR antibody)

Vemurafenib (US/EU) (PLX4032 / Melanoma Adjuvant / BRAF inhibitor)

Quizartinib (US/EU/Asia) (AC220 / AML-2nd / FLT3-ITD inhibitor)

Quizartinib (US/EU/Asia) (AC220 / AML-1st / FLT3-ITD inhibitor)

Pexidartinib (US/EU) (PLX3397 / TGCT / CSF-1R/KIT/FLT3-ITD inhibitor)

Laninamivir (US/EU) (CS-8958 / Anti-influenza / out-licensing with Biota)

Mirogabalin (US/EU) (DS-5565 / Fibromyalgia / α2δ ligand)

Mirogabalin (JP/Asia) (DS-5565 / DPNP/ α2δ ligand)

Mirogabalin (JP/Asia) (DS-5565 / PHN / α2δ ligand)

VN-0105 (JP) (DPT-IPV / Hib vaccine)

Laninamivir (JP) (CS-8958 / Anti-influenza / nebulizer)

Esaxerenone (JP) (CS-3150 / DM nephropathy / MR antagonist)

Patritumab (EU) (U3-1287 / Anti-HER3 antibody)

Pexidartinib (US) (PLX3397 / Glioblastoma / CSF-1R/KIT/FLT3-ITD inhibitor)

DS-1647 (JP) (Glioblastoma / G47Δ virus)

Quizartinib (JP) (AC220 / AML-2nd / FLT3-ITD inhibitor)

DS-1040 (US/EU/JP) (Acute ischemic stroke / TAFIa inhibitor)

DS-2330 (Hyperphosphatemia)

DS-9231/TS23 (Thrombosis / α2-PI inactivating antibody)

DS-3032 (US/JP) (MDM2 inhibitor)

PLX7486 (US) (FMS / TRK inhibitor)

PLX8394 (US) (BRAF inhibitor)

DS-6051 (US/JP) (NTRK/ROS1 inhibitor)

PLX9486 (US) (KIT inhibitor)

DS-3201 (JP/US) (EZH1/2 inhibitor)

PLX73086 (US) (CSF-1R inhibitor)

PLX51107 (US) (BRD4 inhibitor)

DS-1971 (Chronic pain)

DS-1501 (US) (Osteoporosis / Anti-Siglec-15 antibody)

DS-7080 (US) (AMD / Angiogenesis inhibitor)

DS-2969 (US) (Clostridium difficile infection /GyrB inhibitor)

DS-5141 (JP) (DMD / ENA oligonucleotide)

VN-0102/JVC-001 (JP) (MMR vaccine)

Hydromorphone (JP) (DS-7113 / Cancer pain / Opioid μ-receptor agonist) <Injection>

CL-108 (US) (Acute pain / Opioid μ-receptor agonist)

Intradermal Seasonal Influenza Vaccine (JP) (VN-100 / prefilled i.d. vaccine for seasonal flu)

VN-0107/MEDI3250 (JP) (Nasal spray flu vaccine)

Major R&D Pipeline DS-8273 (US)

(Anti-DR5 antibody)

DS-8201 (JP/US) (anti-HER2 ADC）

DS-1123 (JP) (Anti-FGFR2 antibody)

U3-1402 (JP) (Anti-HER3 ADC)

DS-1001 (JP) （IDH1m inhibitor）

41

As of July 2017

Contact address regarding this material

Daiichi Sankyo Co., Ltd.

Corporate Communications Department TEL: +81-3-6225-1126

Email: DaiichiSankyoIR@daiichisankyo.co.jp